Immunomodulation of pembrolizumab plus docetaxel for the treatment of r/m SCCHN after platinum failure
Phase of Trial: Phase I/II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Docetaxel (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Sep 2017 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.
- 04 Sep 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
- 09 Mar 2016 New trial record